ID | 114665 |
タイトル別表記 | セレコキシブによるFKBP5を介したPD-L1の発現低下は, 悪性神経膠腫モデルにおける抗PD-1抗体医薬による抗腫瘍効果を増強する
FKBP5 regulation on anti-PD-1 therapy
|
著者 |
Shono, Kenji
Tokushima University
Shikata, Eiji
Tokushima University
Yamaguchi, Tadashi
Tokushima University
Kitazato, Keiko
Tokushima University
Sampetrean, Oltea
Keio University
Saya, Hideyuki
Keio University
|
キーワード | glioblastoma
PD-1
PD-L1
FKBP5
celecoxib
|
資料タイプ |
学位論文
|
抄録 | Background. Antitumor therapies targeting programmed cell death-1 (PD-1) or its ligand-1 (PD-L1) are used in various cancers. However, in glioblastoma (GBM), the expression of PD-L1 varies between patients, and the relationship between this variation and the efficacy of anti-PD-1 antibody therapy remains unclear. High expression levels of PD-L1 affect the proliferation and invasiveness of GBM cells. As COX-2 modulates PD-L1 expression in cancer cells, we tested the hypothesis that the COX-2 inhibitor celecoxib potentiates anti-PD-1 antibody treatment via the downregulation of PD-L1.
Methods. Six-week-old male C57BL/6 mice injected with murine glioma stem cells (GSCs) were randomly divided into four groups treated with vehicle, celecoxib, anti-PD-1 antibody, or celecoxib plus anti-PD-1 antibody and the antitumor effects of these treatments were assessed. To verify the mechanisms underlying these effects, murine GSCs and human GBM cells were studied in vitro. Results. Compared with that with each single treatment, the combination of celecoxib and anti-PD-1 antibody treatment significantly decreased tumor volume and prolonged survival. The high expression of PD-L1 was decreased by celecoxib in the glioma model injected with murine GSCs, cultured murine GSCs, and cultured human GBM cells. This reduction was associated with post-transcriptional regulation of the co-chaperone FK506-binding protein 5 (FKBP5). Conclusions. Combination therapy with anti-PD-1 antibody plus celecoxib might be a promising therapeutic strategy to target PD-L1 in glioblastoma. The downregulation of highly-expressed PD-L1 via FKBP5, induced by celecoxib, could play a role in its antitumor effects. |
掲載誌名 |
Neuro-Oncology Advances
|
ISSN | 26322498
|
出版者 | Oxford University Press|the Society for Neuro-Oncology|the European Association of Neuro-Oncology
|
巻 | 2
|
号 | 1
|
開始ページ | vdz058
|
発行日 | 2019-12-26
|
備考 | 内容要旨・審査要旨・論文本文の公開
本論文は, 著者Izumi Yamaguchiの学位論文として提出され, 学位審査・授与の対象となっている。 |
権利情報 | © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
博士論文全文を含む
|
文科省報告番号 | 甲第3370号
|
学位記番号 | 甲医第1453号
|
学位授与年月日 | 2020-03-23
|
学位名 |
博士(医学)
|
学位授与機関 |
徳島大学
|
部局 |
病院
医学系
|